Difficulty: Medium
Average Score: 95%
Practice
Which of the following statements are FALSE?
Correct answer
C
Rationale
The correct answer is C) Metformin is usually first-line treatment for GDM. This statement is FALSE because metformin is not typically considered first-line treatment for gestational diabetes mellitus (GDM). Insulin is generally the recommended first-line therapy for GDM due to its long-standing safety profile for both the mother and the fetus.
Option A is incorrect because both metformin and glibenclamide do cross the placenta, which raises concerns about their potential effects on the fetus. Option B is incorrect because while both metformin and glibenclamide can be used as alternatives to insulin in the management of GDM, they are not considered first-line treatments.
Option D is incorrect because although insulin has strong evidence supporting its safety and effectiveness in managing GDM, it is not the only suitable option. However, due to its well-established safety profile, insulin remains a common choice for managing GDM, especially in cases where other medications may not be appropriate.
In an educational context, understanding the appropriate management of GDM is crucial for healthcare providers working with pregnant individuals. Knowing the nuances of different treatment options, their benefits, risks, and evidence-based practices helps ensure optimal outcomes for both the mother and the baby. It is essential to stay informed about the most current guidelines and recommendations to provide the best possible care for pregnant patients with GDM.
Option A is incorrect because both metformin and glibenclamide do cross the placenta, which raises concerns about their potential effects on the fetus. Option B is incorrect because while both metformin and glibenclamide can be used as alternatives to insulin in the management of GDM, they are not considered first-line treatments.
Option D is incorrect because although insulin has strong evidence supporting its safety and effectiveness in managing GDM, it is not the only suitable option. However, due to its well-established safety profile, insulin remains a common choice for managing GDM, especially in cases where other medications may not be appropriate.
In an educational context, understanding the appropriate management of GDM is crucial for healthcare providers working with pregnant individuals. Knowing the nuances of different treatment options, their benefits, risks, and evidence-based practices helps ensure optimal outcomes for both the mother and the baby. It is essential to stay informed about the most current guidelines and recommendations to provide the best possible care for pregnant patients with GDM.